Transcript of Earnings conference call pertaining to financial results of the Company for the quarter and year ended March 31, 2026
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Solara Active Pharma Sciences reported its strongest Q4 FY26 performance in 8 quarters with revenue of INR 392 crores (12% Q-o-Q growth), gross margins of 47% (improvement of 170 bps Q-o-Q), and EBITDA of INR 61 crores (65% Q-o-Q growth). The company reduced debt by INR 158 crores in FY26 (21% reduction) and aims to become debt-free by FY29. The ibuprofen business continues to be a drag with negative EBITDA, and bankers have been appointed to evaluate strategic options with a decision expected in H1 FY27. The base business operates at 26% EBITDA margin with 54% gross margins, contributing 75% of sales from developed markets. Management plans to file 4-5 DMFs annually starting FY26, with revenues from new filings expected in FY29-30. The company has 30% spare capacity in existing facilities and is not planning greenfield expansion.
Strong Q4 recovery with margin expansion signals operational turnaround gaining traction. Debt reduction progress and clear timeline for ibuprofen resolution are positive for shareholders. The company's focus on high-margin base business and operational leverage should support earnings growth, though the ibuprofen divestment decision remains a key near-term catalyst.